IGF2BP1-m6A-THBS1 Axis Drives Macrophage Fibrotic Reprogramming

Study Background and Research Question

Pulmonary fibrosis (PF) is a progressive and often fatal disorder marked by excessive extracellular matrix deposition and fibroblast proliferation, resulting in irreversible lung architecture remodeling and respiratory failure. While the etiology of many PF cases—especially idiopathic pulmonary fibrosis (IPF)—remains unclear, there is growing evidence that macrophage-driven inflammatory and fibrotic processes are central to disease progression. Macrophages, through their polarization states, influence the balance between inflammation and tissue remodeling, with M1 phenotypes typically promoting inflammation and M2 phenotypes contributing to fibrosis. Recent advances have implicated not only cytokine-driven signaling but also metabolic and posttranscriptional regulatory mechanisms in driving macrophage behavior. Of particular interest is N6-methyladenosine (m6A) modification, the most abundant internal mRNA modification in eukaryotes, which dynamically regulates gene expression and has been linked to fibrotic disease states. However, the specific role of m6A reader proteins, such as insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), in orchestrating macrophage metabolism and polarization during PF has remained insufficiently defined. The current study directly investigates this gap, focusing on the IGF2BP1-m6A-THBS1 axis in macrophage-mediated fibrogenesis (Hu et al., 2025).

Key Innovation from the Reference Study

The central innovation of this study lies in identifying a novel regulatory circuit in pulmonary fibrosis: the m6A-dependent stabilization of thrombospondin-1 (THBS1) mRNA by IGF2BP1 in macrophages, and the subsequent activation of TLR4 signaling that drives M2 polarization and glycolytic reprogramming. While m6A modifications and IGF2BP1 have both been individually associated with fibrotic progression, this work defines a mechanistic pathway linking epigenetic, metabolic, and immunological processes in the context of disease. The demonstration that THBS1 acts not only as a downstream target but also as a functional bridge to TLR4-mediated signaling provides significant depth to our understanding of how macrophage activation and cytokine release are coupled to metabolic state and profibrotic activity.

Methods and Experimental Design Insights

The investigators utilized a combination of in vivo and in vitro strategies to dissect the IGF2BP1-m6A-THBS1 axis. A murine model of bleomycin-induced pulmonary fibrosis was employed to recapitulate key pathological features, including inflammatory infiltrates and matrix accumulation. IGF2BP1 expression was manipulated via knockdown approaches, and subsequent histological, biochemical, and molecular analyses (including Ashcroft fibrosis scoring, hydroxyproline quantification, and macrophage immunophenotyping) were conducted to assess fibrotic progression. At the cellular level, primary macrophages and embryonic lung fibroblasts (ELFs) were isolated to study polarization and metabolic changes. RNA immunoprecipitation and mRNA stability assays confirmed the direct binding and stabilization of THBS1 mRNA by IGF2BP1 in an m6A-dependent manner. Functional rescue experiments, involving THBS1 and TLR4 overexpression, were key in establishing the causal roles of these mediators in reversing the effects of IGF2BP1 knockdown. Glycolytic flux was evaluated using standard assays for HK2, LDHA, PKM2 expression, lactate production, glucose consumption, and ATP generation.

Protocol Parameters

• Bleomycin-induced fibrosis: Administer bleomycin intratracheally to C57BL/6 mice at 2–3 U/kg to model PF pathology.
• IGF2BP1 knockdown: Deliver siRNA or shRNA via lentiviral vectors; verify knockdown efficiency in alveolar macrophages by qPCR and Western blot.
• Macrophage polarization assay: Isolate mouse peritoneal or bone marrow-derived macrophages, stimulate with IL-4/IL-13 for M2 induction, and assess markers (CD163, Arg1, Ym1) by flow cytometry or RT-qPCR.
• Glycolytic metabolism assessment: Measure glucose uptake, lactate secretion, and ATP content in cultured macrophages using colorimetric or luminescent kits; evaluate enzyme expression by Western blot.
• THBS1 and TLR4 transfection: Use plasmid-based overexpression systems; confirm protein expression and downstream signaling by immunoblotting.
• Histological evaluation: Score fibrosis using Ashcroft scale on lung tissue sections; quantify hydroxyproline for collagen content.

Core Findings and Why They Matter

The study's primary findings can be summarized as follows:

• IGF2BP1 is upregulated in macrophages during PF, and its knockdown mitigates lung pathology, reducing inflammatory infiltration, fibroblast accumulation, and collagen deposition (Hu et al., 2025).
• Loss of IGF2BP1 reduces expression of fibrotic and M2 macrophage markers (TGF-β1, α-SMA, Collagen-I/III, Arg1, CCL18, Ym1, CD163, IL-6, IL-1β, TIMP1) and lowers the proportion of CD68+/CD163+ (M2-like) macrophages.
• IGF2BP1 binds and stabilizes THBS1 mRNA in an m6A-dependent fashion. THBS1 overexpression rescues the suppressed M2 polarization and glycolysis caused by IGF2BP1 knockdown, restoring HK2, LDHA, PKM2 levels, and metabolic activity.
• THBS1 directly interacts with TLR4, and TLR4 overexpression reverses the effects of THBS1 knockdown, reestablishing M2 polarization and glycolytic flux.

Collectively, these results define a new regulatory axis—IGF2BP1/THBS1/TLR4—that connects epigenetic mRNA modification to metabolic and immune reprogramming in disease pathogenesis. This mechanistic insight advances understanding of macrophage-driven fibrotic progression, directly linking posttranscriptional regulation to osteoclast progenitor proliferation, macrophage activation, and inflammatory response modulation.

Comparison with Existing Internal Articles

Several recent articles have explored both the role of macrophage biology in fibrotic disease and the utility of recombinant cytokines for experimental manipulation. The synthesis in 'Recombinant Mouse M-CSF: Mechanistic Insights and Strategy' supports the centrality of M-CSF in promoting macrophage survival and functional programming, including the ability to model macrophage-mediated tissue remodeling and fibrogenesis. The article 'IGF2BP1 Drives Macrophage Glycolysis and Fibrosis via THBS1 mRNA Stabilization' provides complementary coverage, highlighting the intersection of metabolic reprogramming and immune polarization in fibrotic progression, closely mirroring the reference study's mechanistic findings. Furthermore, 'IGF2BP1-m6A-THBS1 Axis Drives Macrophage Polarization in Pulmonary Fibrosis' reinforces the emerging consensus on the m6A/IGF2BP1/THBS1/TLR4 pathway as a key driver of macrophage phenotype and disease state. The present reference article extends these insights by providing direct evidence of m6A-dependent THBS1 mRNA stabilization and functional rescue using targeted overexpression, thus offering a more granular dissection of the regulatory nodes.

Limitations and Transferability

While the mechanistic clarity of the IGF2BP1/THBS1/TLR4 axis is a major advance, several limitations merit consideration. The primary evidence derives from murine models and in vitro manipulation of mouse macrophages and fibroblasts. Although these systems reproduce salient features of human PF, species-specific differences in macrophage biology and m6A reader-target interactions may influence translational potential. The study does not evaluate long-term outcomes or test therapeutic interventions targeting this axis in vivo. Moreover, the role of other m6A readers, upstream methyltransferases, or the broader cytokine milieu remains to be elucidated. Thus, while the new regulatory link is robustly established in the experimental context, extrapolation to human disease should proceed cautiously and warrants further clinical investigation.

Research Support Resources

To experimentally model macrophage-driven fibrosis or interrogate the IGF2BP1/THBS1/TLR4 pathway, reliable reagents for macrophage culture and functional assays are essential. Researchers can utilize Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021) to support the survival, proliferation, and polarization of mouse macrophages in vitro. This reagent, produced in a HEK293 system and confirmed for high biological activity, facilitates robust and reproducible macrophage models for studying metabolic and fibrotic reprogramming. For further methodological strategies and mechanistic insights, consult the linked internal articles and reference study.